FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379523321> ?p ?o ?g. }

• W4379523321 endingPage "513" @default.
• W4379523321 startingPage "513.2" @default.
• W4379523321 abstract "Background Androgen deprivation therapy (ADT) in prostate cancer (PCa) is associated with an increased risk of bone fragility including bone loss, osteoporosis and fractures. Although international recommendations suggest performing dual-energy x-ray absorptiometry (DXA) at the initiation of treatment, less than 10% of patients do it. The implementation of a standardised clinical care pathway could help prevent bone-related complications in patients starting ADT. Objectives To improve screening for bone fragility in patients starting ADT for PCa by setting up a clinical care pathway. To describe the characteristic of patients with PCa starting ADT. Methods The radiation oncologists, medical oncologists or urologists from a tertiary center systematically referred all patients starting any ADT for PCa to our rheumatology department for a bone-health assessment including a DXA and clinics with a bone specialist. The effectiveness of the pathway was assessed by the number of patients who performed DXA at the initiation of ADT. Results Between March and December 2022, 116 of the 119 patients (97%) referred to our department were able to have a bone assessment within an average of 36 +/- 15 days. The three patients not seen in the care pathway did not wish to come for a new medical appointment. Among the 116 patients, mean age at first visit was 75+/-7 years old, mean BMI 26.9 +/- 4.7 kg/m 2 , 56% were previous or current smoker and Charlson Comorbidity Index was 4.75 +/- 2.5 with 20% diabetes, 15% peripheral vascular disease, 11% coronaropathy and 10% chronic kidney disease. Regarding PCa, 65% were on a localized or locally-advanced stage while 35% were metastatic and overall, 44% presented with a high risk histo-pronostic score (ISUP 4 or 5). Sixty-four patients (55%) were scheduled to concomitant prostatic external beam radiation, as initial or salvage therapy. Median PSA at diagnosis was 16 ng/ml (8.8-38.5) At inclusion, 70% of patients were newly-diagnosed PCa while 30% were recurrent PCa. ADT was prescribed alone for 65% of patients or in combination with new hormone-therapy (NHT) for 35% of patients and 26% with concomitant corticosteroids with a mean dose of 10 +/-4 mg. The mean duration of previous ADT for relapsing patients was 16 +/- 20 months. Regarding bone disease, 11% patients had previous bone fracture mainly in the spine, 15% had familial history of hip fracture and 20% reported a fall within the past year. Forty-two percent of patients had vitamin D supplementation but only one was previously treated with an anti-osteoporotic agent. Finally, 114 patients had a DXA. A lumbar BMD T-score ≤-2.5 was found for 9 patients, ≤ -2 for 17 patients. A hip BMD T-score ≤ -2.5 was found for 12 patients and ≤ -2 for 35 patients. A T-score ≤ -2.5 to at least one site was found in 18 patients (16%) and ≤ -2 for 41 patients (35%). After BMD assessment, an anti-osteoporotic treatment was prescribed in 40% of patients with bisphosphonate (71%) or denosumab (29%). Conclusion This clinical care pathway allowed 97% of patients to have a bone assessment when starting ADT for PCa. This cohort of 116 patients confirms the high prevalence of low BMD among these patients and the need to screen and treat patients to prevent bone-related complications. Acknowledgements I thanks Mioranirainy DERAHARIJAONA and Catherine LE BOURLOUT for their help in collecting clinical data. Disclosure of Interests None Declared." @default.
• W4379523321 created "2023-06-07" @default.
• W4379523321 creator A5008540435 @default.
• W4379523321 creator A5009043248 @default.
• W4379523321 creator A5009280176 @default.
• W4379523321 creator A5019843468 @default.
• W4379523321 creator A5020075220 @default.
• W4379523321 creator A5028242882 @default.
• W4379523321 creator A5033054923 @default.
• W4379523321 creator A5039277233 @default.
• W4379523321 creator A5048640756 @default.
• W4379523321 creator A5050813045 @default.
• W4379523321 creator A5054972375 @default.
• W4379523321 creator A5059690857 @default.
• W4379523321 creator A5066864566 @default.
• W4379523321 creator A5082228458 @default.
• W4379523321 creator A5086087911 @default.
• W4379523321 creator A5088027363 @default.
• W4379523321 date "2023-05-30" @default.
• W4379523321 modified "2023-10-18" @default.
• W4379523321 title "POS0502 IMPLEMENTATION OF A CLINICAL CARE PATHWAY FOR SYSTEMATIC BONE FRAGILITY ASSESSMENT AT THE INITIATION OF ANDROGEN DEPRIVATION IN PROSTATE CANCER PATIENTS (HORMOS PROJECT)" @default.
• W4379523321 doi "https://doi.org/10.1136/annrheumdis-2023-eular.5760" @default.
• W4379523321 hasPublicationYear "2023" @default.
• W4379523321 type Work @default.
• W4379523321 citedByCount "0" @default.
• W4379523321 crossrefType "journal-article" @default.
• W4379523321 hasAuthorship W4379523321A5008540435 @default.
• W4379523321 hasAuthorship W4379523321A5009043248 @default.
• W4379523321 hasAuthorship W4379523321A5009280176 @default.
• W4379523321 hasAuthorship W4379523321A5019843468 @default.
• W4379523321 hasAuthorship W4379523321A5020075220 @default.
• W4379523321 hasAuthorship W4379523321A5028242882 @default.
• W4379523321 hasAuthorship W4379523321A5033054923 @default.
• W4379523321 hasAuthorship W4379523321A5039277233 @default.
• W4379523321 hasAuthorship W4379523321A5048640756 @default.
• W4379523321 hasAuthorship W4379523321A5050813045 @default.
• W4379523321 hasAuthorship W4379523321A5054972375 @default.
• W4379523321 hasAuthorship W4379523321A5059690857 @default.
• W4379523321 hasAuthorship W4379523321A5066864566 @default.
• W4379523321 hasAuthorship W4379523321A5082228458 @default.
• W4379523321 hasAuthorship W4379523321A5086087911 @default.
• W4379523321 hasAuthorship W4379523321A5088027363 @default.
• W4379523321 hasBestOaLocation W43795233211 @default.
• W4379523321 hasConcept C121608353 @default.
• W4379523321 hasConcept C126322002 @default.
• W4379523321 hasConcept C159110408 @default.
• W4379523321 hasConcept C198451711 @default.
• W4379523321 hasConcept C2776343214 @default.
• W4379523321 hasConcept C2776541429 @default.
• W4379523321 hasConcept C2776886416 @default.
• W4379523321 hasConcept C2777425516 @default.
• W4379523321 hasConcept C2777899217 @default.
• W4379523321 hasConcept C2778373050 @default.
• W4379523321 hasConcept C2779159551 @default.
• W4379523321 hasConcept C2780192828 @default.
• W4379523321 hasConcept C71924100 @default.
• W4379523321 hasConceptScore W4379523321C121608353 @default.
• W4379523321 hasConceptScore W4379523321C126322002 @default.
• W4379523321 hasConceptScore W4379523321C159110408 @default.
• W4379523321 hasConceptScore W4379523321C198451711 @default.
• W4379523321 hasConceptScore W4379523321C2776343214 @default.
• W4379523321 hasConceptScore W4379523321C2776541429 @default.
• W4379523321 hasConceptScore W4379523321C2776886416 @default.
• W4379523321 hasConceptScore W4379523321C2777425516 @default.
• W4379523321 hasConceptScore W4379523321C2777899217 @default.
• W4379523321 hasConceptScore W4379523321C2778373050 @default.
• W4379523321 hasConceptScore W4379523321C2779159551 @default.
• W4379523321 hasConceptScore W4379523321C2780192828 @default.
• W4379523321 hasConceptScore W4379523321C71924100 @default.
• W4379523321 hasIssue "Suppl 1" @default.
• W4379523321 hasLocation W43795233211 @default.
• W4379523321 hasOpenAccess W4379523321 @default.
• W4379523321 hasPrimaryLocation W43795233211 @default.
• W4379523321 hasRelatedWork W1994769697 @default.
• W4379523321 hasRelatedWork W2068398196 @default.
• W4379523321 hasRelatedWork W2113888903 @default.
• W4379523321 hasRelatedWork W2122627708 @default.
• W4379523321 hasRelatedWork W2244851579 @default.
• W4379523321 hasRelatedWork W2301056320 @default.
• W4379523321 hasRelatedWork W2768058331 @default.
• W4379523321 hasRelatedWork W3007366261 @default.
• W4379523321 hasRelatedWork W4225899280 @default.
• W4379523321 hasRelatedWork W2050261170 @default.
• W4379523321 hasVolume "82" @default.
• W4379523321 isParatext "false" @default.
• W4379523321 isRetracted "false" @default.
• W4379523321 workType "article" @default.